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Summary
An understanding of mucosal immunity is essential for the
comprehension of intestinal diseases that are often caused
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by a complex interplay between host factors, environment-
al influences and the intestinal microbiota. Not only im-
provements in endoscopic techniques, but also advances in
high throughput sequencing technologies, have expanded
knowledge of how intestinal diseases develop. This review
discusses how the host interacts with intestinal microbi-
ota by the direct contact of host receptors with highly con-
served structural motifs or molecules of microbes and also
by microbe-derived metabolites (produced by the microbe
during adaptation to the gut environment), such as short-
chain fatty acids, vitamins, bile acids and amino acids.
These metabolites are recognised by metabolite-sensing re-
ceptors expressed by immune cells to influence functions
of macrophages, dendritic cells and T cells, such as migra-
tion, conversion and maintenance of regulatory T cells and
regulation of proinflammatory cytokine production, which
is essential for the maintenance of intestinal homeostasis
and the development of intestinal diseases, such as inflam-
matory bowel diseases. First interventions in these com-
plex interactions between microbe-derived metabolites and
the host immune system for the treatment of gastrointest-
inal diseases, such as modification of the diet, treatment
with antibiotics, application of probiotics and faecal micro-
biota transplantation, have been introduced into the clin-
ic. Specific targeting of metabolite sensing receptors for
the treatment of gastrointestinal diseases is in development.
In future, precision medicine approaches that consider in-
dividual variability in genes, the microbiota, the environ-
ment and lifestyle will become increasingly important for
the care of patients with gastrointestinal diseases.
Key words: ulcerative colitis, Crohn’s disease,
macrophages, dendritic cells, immune system, metabolites,
microbiome, metabolite recognition receptors
Introduction
Every individual has to eat and drink and most people have
experienced symptoms (such as nausea, abdominal pain,
vomiting or diarrhoea) that originate from the digestive
tract at least at one point during their life. To study, dia-
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gnose and treat disorders of the digestive tract, gastroenter-
ology is a medical specialty with a constant need for new
technological devices. Advances in imaging technologies,
especially the development of high-resolution endoscopes,
have revolutionised the way in which gastrointestinal dis-
eases are examined [1]. Nowadays endoscopes are not only
used as diagnostic tools, but also for treating patients: to
stop bleedings [2], remove polyps [3], dissect pre- or even
cancerous lesions and [4] to drain extraintestinal cysts into
the gastrointestinal tract [5]. The response to treatments
in patients with inflammatory bowel diseases (IBD) is in
part evaluated by endoscopy (mucosal healing) [6]. Con-
focal endomicroscopy can be used to predict relapses by
determining cell shedding and barrier loss [7] and predict
the response to antitumour necrosis factor (TNF) therapies
by detecting in vivo fluorescein-labelled anti-TNF antibod-
ies [8]. Even parts of the microflora (i.e., Helicobacter
pylori) can be visualised with confocal endomicroscopy
[9]. However, gastrointestinal diseases, such as IBD, are
very complex. IBD is caused by the interplay of various ge-
netic, environmental and immunological factors [10]. IBD
manifests in different phenotypes and requires complicated
therapies that have to be tailored individually for every pa-
tient in an effort to achieve precision medicine [11, 12].
There have been 163 gene loci identified that are associ-
ated with IBD [13]. However, only three main loci pre-
dict the clinical phenotype of IBD; for example, NOD2 is
associated with ileal Crohn’s disease and HLA susceptib-
ility is associated with colonic Crohn’s disease. No vari-
ant is able to predict disease progression, which can so
far only be predicted by epidemiological or environment-
al factors, such as age of disease onset or smoking [14].
Mucosal immunology together with genetics, microbiology
and virology is essential to explain interindividual differ-
ences between patients [15]. The importance of immuno-
logical factors in gastrointestinal diseases is highlighted by
the fact that most lymphocytes in the human body are loc-
ated within the digestive tract [16, 17], where they have to
deal with a high abundance of microbial consortia (up to
1014 organisms, exceeding our own cell number by a factor
of 10) [18, 19], viruses and bacteriophages [20]. There is
a growing tendency to consider humans as superorganisms
consisting of cells and genes of eukaryotic and prokaryotic
origin. Both prokaryotic and eukaryotic factors affect our
behaviour and physiological processes (uptake and meta-
bolism of food products, utilisation of vitamins, defence
against pathogens). Throughout most of our life this su-
perorganism is perfectly adapted to our needs [21]. In rare
circumstances, however, the normal function of the super-
organism is disturbed and diseases develop. The inability
of the mucosal immune system to ignore or tolerate our
own microbial flora leads to the development of not only
gastrointestinal diseases, such as coeliac disease [22], IBD
[23] or gastrointestinal cancers [24], but also to diseases
at other body sites, such as rheumatoid arthritis [25], type
I diabetes [26], multiple sclerosis [27], nonalcoholic ste-
atosis hepatitis [28, 29], obesity [30] and neurodevelop-
mental disorders, including autism spectrum disorder [31].
In order to understand the disease course and to help our
patients, a detailed analysis of the host mucosal immune
system is essential. In this review we outline critical host-
microbial interactions and discuss potential future lines of
research in mucosal immunity.
It all starts at or even before birth
As embryos we develop in a sterile intrauterine environ-
ment that prevents rejection of the foreign foetus by the
mother [32]. The placenta forms a barrier that separates
not only the mother’s immune system from the foetus, but
also prevents the passage of microorganisms into the foetus
[33]. However, bacterial products, such as lipopolysacchar-
ides (LPS) or bacterial metabolites are able to cross the
placenta to programme the development of the foetus. For
example, neutralisation of LPS in stressed animals pre-
vents abortion of the foetus [34]. During birth the baby
is exposed to multiple prokaryotic organisms located in
the vaginal tract, an overwhelming environmental stressor.
Several mechanisms enable the baby to survive the first
contacts with microbes [35]: the expression levels of Toll-
like receptor 3 (TLR3) [36], the antimicrobial peptides re-
generating islet-derived proteins (REG) 3-β and -γ, the
α-defensins, the cytokines interleukin (IL)-18 and IL-15
and the proliferation-inducing ligand APRIL are reduced
as compared with adults [35]. Conversely, the expression
of cathelicidin-related antimicrobial peptide, IL-27, trans-
forming growth factor-β (TGF-β) and thymic stromal
lymphopoietin is increased in the neonate [35]. Further-
more, monocyte-derived cells replace yolk sac derived
macrophages at the time of birth [37]. CD44- and
CD69-expressing T and B cells that populate the lamina
propria prevent overwhelming immune responses to col-
onisation with the bacterial consortia [38]. Activation of
CD69 leads to the production of the immuneregulatory
cytokine TGF-β and downregulation of the production of
proinflammatory cytokines [39]. It needs to be pointed out
that the microbial consortia of newborns are not stable at
the beginning of the colonisation period. The final com-
position of the flora depends on the mode of delivery, en-
vironmental hygiene status, diet and medication. At birth,
facultative anaerobic bacteria, including Escherichia coli,
Firmicutes species and Staphylococcus species, dominate
in the first few days as shown by the analysis of the new-
born’s meconium [40]. When oxygen is deprived, the an-
aerobic bacteria, such as Bacteroides, Clostridium and Bi-
fidobacterium, replace E. coli, Firmicutes species and Sta-
phylococcus species [40]. At the time when the baby is
weaned from the mother’s milk and regular food is intro-
duced around 1 year of age, the composition of the intestin-
al flora stabilises. In adults, the dominant bacterial genera
are Bacteroides, Clostridium, Fusobacterium, Eubacteri-
um, Ruminococcus, Peptococcus, Peptostreptococcus and
Bifidobacterium with predominance of the Bacteroides,
Prevetolla or the Ruminococcus enterotypes [41].
However, the intestinal microflora and the host mucosal
immune system need to be seen as one entity, in which the
microflora shapes the immune system and in which the im-
mune system influences the composition of inhabitants in
our gut. During the neonatal period, the immune system
and the intestinal flora form one entity, influencing each
other until equilibrium is reached. At this stage, the im-
mune system is primed and the first weeks of life have been
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considered as a “window of opportunities” that might im-
pact the development of diseases in later life, such as al-
lergies and asthma [42, 43]. The “foetal programming hy-
pothesis” suggests that microbial metabolites of the mother
influence the intrauterine development of the foetus with
impact on diseases in later life [44]. The “hygiene hy-
pothesis” proposed that a reduction of the microbial load
during the neonatal period and childhood influences the
development of autoimmune diseases [45]. Namely, the in-
creased prevalence of IBD [46], atopic and allergic dis-
eases [47] and other autoimmune diseases in industrialised
countries have been attributed to the improved hygiene
conditions during the neonatal period and vaccination pro-
grammes during childhood [45]. Children born in farming
conditions rich with microbial antigen load are protected
from the development of asthma [48]. These data strongly
indicate that the composition of the bacterial flora and the
priming of the immune system influence the development
of diseases later in life.
Host-microbe interactions drive
intestinal diseases
The outcome of host-microbe interactions depends on (i)
the genetic background of the host and (ii) the microbes
that challenge us [49]. When a pathogen, such as Salmon-
ella or Yersinia, is ingested, infectious gastroenteritis will
likely develop. There have been increasing numbers of
pathobionts described. A pathobiont is a potentially patho-
genic organism that lives as a symbiont under normal con-
ditions [50]. In mice, segmented filamentous bacteria are
an example of pathobionts, as they drive the generation
of IL-17 producing helper T cells (Th17 cells) in the gut,
which protects the animals from infection with Citrobacter
rodentium [51]. However, animals colonised with segmen-
ted filamentous bacteria may be prone to develop autoim-
mune diseases, such as rheumatoid arthritis [25]. In pa-
tients with Crohn’s disease, increased numbers of adherent-
invasive E. coli have been observed, which may play a role
in driving IBD in genetically predisposed individuals [52].
Nevertheless, one single species has not been identified as
the sole driver of IBD. Rather, changes of the intestinal
microflora have been observed, such as reduced diversity
and increased abundance of mucosal-associated aero-toler-
ant bacteria [53]. It needs to be pointed out that most stud-
ies have investigated microbial consortia in biopsies from
the rectum. Although this method may allow prediction of
Figure 1
Identification of disease-associated bacterial consortia in the
gut. The bacteria coated with IgA in faecal material can be labelled
with an antibody directed against IgA. IgA-coated bacteria are then
enriched by magnetic-activated cell sorting (MACS), purified by
fluorescence-activated cell sorting (FACS) and sequenced by 16S
ribosomal RNA sequencing to identify the IgA coated genera.
the course of some diseases, it does not represent changes
in the upper parts of the digestive tract that occur, for in-
stance, in ileitis [23]. Preparation for colonoscopy disturbs
the composition of microbial consortia in the gastrointest-
inal tract [54] and there is currently no technique available
to take biopsies of the upper parts of the gastrointestinal
tract in unprepared patients. To overcome these difficulties,
researchers have hypothesised that, in contrast to regular
commensal bacteria, IBD-driving bacteria induce high af-
finity IgA responses and become highly coated with IgA
[55]. Identification of IgA-coated bacterial genera (fig. 1),
together with the genetic characteristics of the host, may in
the future provide fingerprints of the changes in individual
patients with IBD.
Host responses to the intestinal flora
Conceptually, the host immune system either (i) ignores
the microbiota or (ii) actively tolerates the microbiota [17].
This means that constituents of the microbiota are not dis-
seminated into the host, to prevent sepsis. Lamina propria
dendritic cells sample intestinal bacteria and transport
bacterial-derived antigens to mesenteric lymph nodes, but
not further [56]. When the intestinal barrier is breached,
as in patients with intestinal inflammation, the liver serves
as a second line of defence [57]. In certain circumstances,
such as autoimmune uveitis, the intestinal microflora activ-
ates autoreactive T cells in a noncognate manner in the gut,
inducing autoimmunity at distant sites such as the immune-
privileged eye [58]. There is emerging data that microor-
ganisms train innate and adaptive immune cells to deal
better with microbial encounters [59]. For instance, ex-
posure to microbial products trains innate immune cells,
such as macrophages and intestinal epithelial cells, by epi-
genetic modifications to tolerate re-exposures [60]. This is
an active process by which the innate immune system is
able to deal with the microflora. For example, re-expos-
ure of intestinal epithelial cells to LPS leads to diminished
cell responses, meaning that “innate tolerance” to bacterial
products has developed [61]. Adaptive immunity includes
the clonal expansion of T and B cells that provide life-long
antigen-specific immune responses. The innate and adapt-
ive immune system adapts to the challenges provided by
the intestinal flora in active processes to prevent potential
damage to the host.
Recognition of bacterial products and
metabolites by the host
The recognition of bacterial products by the host is a key
event, which leads to the initiation of mucosal immune re-
sponses [62, 63]. Pattern recognition receptors recognise
pathogen-associated molecular patterns – highly conserved
structural motifs or molecules that are common to a broad
range of microbes. For example, LPS is a common part
of the cell wall of Gram-negative bacteria and binds to
the Toll-like receptor TLR4 [64]. Recent work indicated
that not only the recognition of bacterial motifs but also
of bacterial-derived metabolites, produced by the bacteria
during adaptation to the local environment in the gut, can
modulate immune responses of the host (fig. 2). For ex-
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ample, bacteria-derived adenosine triphosphate is recog-
nised by purinergic P2Y and P2X receptors that are ex-
pressed by CD70highCD11clow myeloid cells to drive Th17
cell responses in the gut [65]. This can explain the reduced
number of Th17 cells in the intestinal lamina propria of
germ-free animals [66]. Gut bacteria metabolise dietary
fibres in the distal colon to short-chain fatty acids (SCFA),
such as butyrate. These SCFA are recognised by the G
protein-coupled receptor (GPR) 41 (free fatty acid receptor
[FFAR] 3) and GPR43 (FFAR2) [67]. The recognition of
SCFA by GPR43 leads to the production of anti-inflammat-
ory cytokines, promotion of regulatory T cells in the mu-
cosa and maintenance of epithelial integrity [68]. In table
1, we have summarised receptors that recognise bacterial-
derived metabolites.
Effects of short-chain fatty acid recognition on the host
SCFA with a carbon length of 2 to 6, such as butyrate,
propionate, formate, isobutyrate, valerate, isovalerate and
acetate are the result of the bacterial fermentation of fibres,
in particular nondigestable polysaccharides [69]. The
SCFA are beneficial for the host as intestinal epithelial cells
utilise them as an energy resource in mitochondrial respir-
ation [70]. Furthermore, intestinal epithelial cells bathed in
SCFA exhibit reduced autophagy [70]. Mitochondrial res-
piration and regulation of autophagy both help to maintain
the integrity of the intestinal barrier and to prevent intestin-
al barrier breach as, for example, observed in patients with
IBD [70]. SCFA are recognised by GPR41 [71], GPR43
[71] and GPR109A [72]. Signalling through GPR43 in-
hibits inflammatory pathways as demonstrated in GPR43
knockout animals, which develop rheumatoid arthritis,
asthma and colitis [68]. SCFA regulate the suppressive
functions of regulatory T cells (Treg cells) through expres-
Figure 2
Not only conserved structural motifs of microorganisms, but also
bacteria-derived metabolites are recognised by the host immune
system. A. Pattern recognition receptors, such as Toll-like
receptors, the scavenger receptors, the C type lectins, the RIG-I-
like or the NOD-like receptors recognise pathogen-associated
molecular patterns, which are highly conserved structural motifs or
molecules common to microbes and viruses. B. Intestinal bacterial
consortia metabolize food products and bile acids to short chain
fatty acids (SCFA), secondary bile acids or vitamins. The G protein
coupled receptor (GPR) recognizes SCFA, the intracellular
farnesoid X receptor (FXR) and the transmembrane G coupled
receptor 5 (TGR5) sense secondary bile acids and retinoic acid is
recognized by the retinoid X receptor to modulate host responses.
sion of GPR43 [68]. Butyrate alone is able to generate Treg
cells by histone-3-acetylation of the intronic enhancer re-
gion conserved in the noncoding sequence 1 of the fork-
head box protein 3 locus, the master transcription factor in
Treg cells [73]. GPR109A serves as a receptor for bacterial-
derived butyrate and niacin [74]. GPR109A signalling pre-
vents production of inflammatory cytokines by intestinal
macrophages, supports IL-10 production by Treg cells and
inhibits IL-18 production by epithelial cells [75]. This
means that SCFA play a critical role in maintaining host
homeostasis and tolerance of the intestinal microflora. This
is further highlighted by the fact that SCFA enemas can be
used to treat diversion colitis, which is observed in a frac-
tion of patients with diverted colon segments after surgery.
Recognition of long-chain fatty acids by the host
Long-chain fatty acids with a carbon length of 13 to 21 can
be divided into unsaturated fatty acids, essential and satur-
ated fatty acids [76]. Polyunsaturated fatty acids are trans-
formed to conjugated linoleic acids and trans fatty acids
[76]. In germ-free rats, conjugated linoleic acids and trans
fatty acids are significantly reduced in the small and large
intestine [77]. Modified polyunsaturated fatty acids bind to
the intracellular peroxisome proliferator-activated recept-
or (PPAR)-γ and -α. Binding of polyunsaturated fatty acids
to PPAR-γ and -α inhibits nuclear factor kappa-light-chain-
enhancer of activated B-cells (NF-κB) activation and pro-
duction of proinflammatory cytokines [78]. PPAR-γ and -α
agonists are used for the treatment of metabolic syndromes,
such as hyperlipidaemia and diabetes. Microbiota-depend-
ent metabolism of long-chain fatty acids hence affects the
immune system of the host.
Bile acids and the immune system
Primary bile acids are synthesised in the liver, stored in the
gall bladder, secreted in the small intestine, transformed to
secondary bile acids by constituents of the microbiota and
reabsorbed in the ileum [79]. In the small intestine, bile
acids form micelles, which are required for the digestion
of lipids, absorption of vitamins and cholesterol metabol-
ism [79]. Bile acids bind the nuclear farnesoid X receptor
(FXR, also known as NR1H4) [80] and the transmembrane
G protein-coupled receptor TGR5 [81]. Binding of bile
acids to FXR leads to the production of fibroblast growth
factor-15 (FGF15) in the ileum [82]. In turn, FGF15 in-
hibits the bile acid rate-limiting enzyme cholesterol 7α-hy-
droxylase (CYP7A1) in the liver [82]. Recognition of bile
acids by FXR controls the synthesis of bile acids and regu-
lates the available bile pool in the organism [82]. FXR-de-
ficient animals are characterised by bacterial overgrowth,
accumulation of neutrophils and disturbance of the mu-
cosal barrier in the ileum [83]. This means that bile acids
are an important factor in preventing dysbiosis. Bile acids
also modulate the immune response of the host. Two ways
in which bile acids modulate the function of macrophages
have been described. After binding to the intracellular FXR
receptor, the NF-κB-nuclear receptor co-repressor 1
(NcoR1) complex is stabilised and prevents the binding
of the transcription factor NF-κB to responsive elements
[84]. On the other hand, after ligation of bile acids to
transmembrane TGR5, cyclic adenosine monophosphate
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(cAMP) is activated and this promotes the interaction of
cAMP response element-binding protein with the transcrip-
tion factor p65 [85]. This interaction prevents the transcrip-
tion of NF-κB-dependent inflammatory cytokine expres-
sion. By this mechanism, TGR5 prevents the development
of colitis [86]. In this process, the intestinal microbiota is
essential since primary bile acids are transformed to sec-
ondary bile acids in the small intestine through microor-
ganisms. Sensing of bile acids is hence of importance for
the maintenance of the integrity of the gut. This is fur-
ther highlighted in the clinic, where bile acid malabsorption
after ileocoecal resections or in Crohn`s disease patients
with severe inflammation of the ileum is a common prob-
lem. This can lead to secondary malabsorption associated
with diarrhoea and malnutrition. Bile acid binding agents,
such as cholestyramine, or the FXR agonist obeticholic
acid have been suggested for the treatment of this condi-
tion.
Vitamins and host responses
Intestinal microorganisms can biosynthesise or modulate
the biosynthesis of vitamins [87]. For example Bifidobac-
terium and Lactobacillus are able to synthesise vitamin
B9 (folate) [88–90]. Vitamins are essential for the normal
growth and development of our organism [87] and also
influence the immune defence. A well-known example is
the vitamin A metabolite retinoic acid [91]. Dietary retinol
(vitamin A1) is metabolised by retinol dehydrogenases to
retinal, which is further metabolised to retinoic acid by ret-
inal dehydrogenases (RALDH) [91]. Retinoic acid binds to
heterodimeric nuclear receptors, which bind to retinoic acid
Figure 3
Constituents of the gut microflora and immune system of the
host metabolise the essential amino acid tryptophan. The
essential amino acid tryptophan is shuttled via the T-type amino
acid transporter 1 (TAT1) across the intestinal barrier, metabolized
by indoleamine-2,3-dioxygenase (IDO) expressed in dendritic cells
(DC) to kynurenine and kynurenic acid. Kynurenine supports the
conversion of T cells to regulatory T cells (Treg); kynurenic acid
binds to the G-protein coupled receptor (GPR) 35 expressed by
macrophages (Mac). Tryptophan is also metabolized by
constituents of the microflora to indole-3-aldehyde, which binds to
the aryl hydrocarbon receptor (AhR) facilitating IL-22 production by
innate lymphoid cells (ILC)
response elements in target genes. Dendritic cells located
in the mesenteric lymph nodes and Peyer’s patches express
the genes aldh1a2 and aldh1a1, which code for RALDH1
and RALDH2 [92]. Retinoic acid synthesised by dendrit-
ic cells imprints the expression of the chemokine recept-
or CCR9 and the integrin α4β7, gut homing receptors re-
sponsible for the migration of T cells to the gut [93, 94].
Furthermore, RALDH is predominantly expressed in dend-
ritic cells at mucosal barriers [95]. Infections at barrier sites
lead to increased RALDH activity [96]. Retinoic acid sup-
ports the TGF-β-dependent conversion of naïve T cells in-
to Treg cells [97], promoting immune tolerance at mucosal
sites. After stimulation of Treg cells with retinoic acid re-
duced expression of the receptor for IL-6 is observed, a cy-
tokine required for the generation of IL-17-producing Th17
cells [98]. Retinoic acid also promotes Th1 differentiation
[99], restrains Th1 plasticity (by inhibition of Th17 fate)
[99] and is required for Th2 responses to parasite infections
[96, 100].
Other dietary vitamins, such as vitamin B12, also modulate
the immune system. Reduced lymphocyte numbers are ob-
served in vitamin B12-deficient patients [101]. Natural
killer cell activity is regulated by vitamin B12 [101]. Vit-
amin B2 (riboflavin) activates mucosal invariant T cells
(MAIT cells) [102]. Vitamin D deficiency is associated
with IBD susceptibility and colitis-associated cancer [103].
Animal studies have shown that the expression of the vit-
amin D receptor by intestinal epithelial cells protects the
gut from inflammation and carcinogenesis [104].
Sensing of amino acids by the immune system
The twenty-two amino acids taken up by our bodies from
the diet are used to synthesise proteins and are also a
source of energy after oxidation to urea and carbon. Nine
amino acids are called essential amino acids, because our
body cannot synthesise them. Amino acids metabolised by
the intestinal microflora can influence the immune sys-
tem [105]. The essential aromatic amino acid tryptophan is
metabolised in the gut by lactobacilli to indole-3-aldehyde
(as summarised in fig. 3) [106].Tryptophan is also trans-
ported across the intestinal barrier by the T-type amino acid
transporter TAT1 (Slc16a10) [107]. Tryptophan is meta-
bolised by indolamin-2,3-dioxygenase (IDO) expressed by
intestinal macrophages and dendritic cells to kynurenine
[108]. Kynurenine can be further metabolised by the
kynurenine transferases I, II and III to kynurenic acid
[105]. The tryptophan metabolites indole-3-aldehyde and
kynurenine are recognised by the aryl hydrocarbon recept-
or (AhR) [109]. Kynurenic acid is recognised by the G-
coupled receptor GPR35 [110]; the kynurenine metabolite
niacin is sensed by the G-coupled receptor GPR109A [74].
Tryptophan is hence consumed from the local tissue-spe-
cific microenvironment by the IDO pathway [111], which
is modulated by the cytokine IL-27 [112]. Reduced trypto-
phan concentrations activate cellular stress response path-
ways, such as the general control nonderepressible
(GCN)-2-kinase and the mammalian target of rapamycin
(mTOR) pathways [113]. In addition, tryptophan metabol-
ites are recognised by specific receptors, such as the AhR
receptors and the GPR35 receptor [111]. Overall, the ac-
tivation of IDO-dependent pathways favours immune sup-
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pression and tolerance [105, 114]. In the gut, the IDO path-
way suppresses colitis [115].
There are also other amino acids involved in the regulation
of immune response [76]. Besides its role in the hepatic
urea cycle, arginine is also a substrate for nitric oxide
and arginase, which are expressed by myeloid cells and
granulocytes [116, 117]. Granulocyte-derived arginase
controls chronic infections by inhibiting cytokine produc-
tion by T cells and T cell proliferation [118]. Thus, amino
acids, the host immune response and intestinal microorgan-
isms have likely developed multiple pathways by which
they interact with each other. We are currently just begin-
ning to dissect the different pathways and do not well un-
derstand the importance of these interactions for the devel-
opment of diseases, such as IBD.
Macrophages express metabolite-
sensing molecules
When the expression of metabolite-sensing molecules are
analysed in available databases, it is striking that not only
the gut epithelium but also macrophages have high ex-
pression levels of the metabolite sensing receptors GPR35
and GPR120, and the purinergic receptors P2Y and P2X.
Located right beneath the intestinal epithelium with the
ability to extend processes between intestinal epithelial
cells into the intestinal lumen, phagocytes are optimally
positioned to sense metabolites derived from the intestinal
microbiota [119]. Intestinal macrophages are continuously
replaced by monocyte-derived cells [17]. In adults, mac-
rophages are low proliferating cells and produce immun-
osuppressive cytokines, such as IL-10, in homeostatic con-
ditions [120]. Intestinal macrophages are highly phagocytic
cells with bactericidal activity enabling them to kill bac-
teria and other microorganisms that have entered the host
[121]. They do not release proinflammatory cytokines after
engulfing a microorganism to avoid uncontrolled inflam-
mation in the gut [122]. Recent work has highlighted the
importance of GPR35, variants of which have been associ-
ated with IBD [123]. Along the intestinal tract the highest
concentrations of this receptor are observed in the ileum.
In the same region, intestinal macrophages have processes
that enter the intestinal lumen to sense microbes and
microbial-derived metabolites [124]. GPR35 is also the
receptor for the chemokine CXCL17 (dendritic cell- and
monocyte-attracting chemokine-like protein) [125]. Small
and large intestinal tissues express CXCL17. It is likely
that GPR35 may position macrophages in the gut to sample
and recognise bacterial derived products and metabolites.
However, formal proof of the importance of GPR35 for the
migration of monocyte-derived cells has not been shown.
The development of knockout cell lines and mouse strains
could be potentially of great value for the dissection of the
function of GPR35 in intestinal tissues.
Table 1: Metabolite-sensing receptors and their ligands (adapted from references [69, 141]).
Receptor / intracellular target Cell Ligand Origin Effect
GPR41 / FFAR3 Adipocytes, enteroendocrine L
cells
Formate, acetate, propionate,
butyrate, pentanoate
Commensal bacteria (digestion
of fibres)
DC maturation, leptin
production, regulation of energy
balance
GPR43 / FFAR2 Innate immune cells,
enteroendocrine L cells,
intestinal epithelial cells, white
adipose tissues
Formate, acetate, propionate,
butyrate, pentanoate
Commensal bacteria (digestion
of fibres)
Gut homeostasis, tumour
suppressor, anti-inflammatory
GPR109A (NIACR1, HM74) Macrophages, intestinal
epithelial cells, neutrophils,
adipocytes
Butyrate and nicotinic acid
(niacin)
Commensal bacteria (digestion
of fibres, tryptophan metabolism)
DC migration, Gut homeostasis,
tumour suppressor, anti-
inflammatory
GPR120 (FFAR4) Macrophages, enteroendocrine
cells in the colon
Long-chain fatty acids Diet, metabolism of commensals Inhibition of TNF and IL-6,
insulin secretion
GPR40 Beta-cells (pancreatic islets),
enteroendocrine K cells
Medium- to long-chain fatty
acids
Diet, metabolism of commensals Insulin secretion, anti-
inflammatory
GPR84 Immune cells Medium-chain fatty acids Diet, metabolism of commensals Not known
GPR35 Monocytes/macrophages, NKT
cells, mast cells
Kynurenic acid,
kysophosphatidic acid, pamoic
acid, CXCL17
Tryptophan metabolism Associated with IBD
GPR91 (SUCNR1) DCs, kidney, adipose tissues Succinate Succinate Proinflammatory,
haematopoiesis, activation of the
renin angiotensin system
IDO1 Macrophages, DCs Tryptophan Diet, metabolism of commensals Promoting Treg differentiation
Purinergic (P2Y and P2X)
receptors
Myeloid cells ATP Commensals Th17 differentiation
FXR, TGR5 Epithelial cells Secondary bile acids Bile acid metabolites through
commensals
Promotion of Treg cells, inhibition
of Th17 cells, anti-inflammatory
properties
Retinoid acid receptors DCs Retinoic acid Diet Gut homing of T cells
FR (B9) Treg cells Vitamins B9 and B12 Commensal microbiota Maintenance of Treg cells
Peroxisome proliferator-
activated receptors gamma and
alpha
Intestinal epithelial cells Polyunsaturated fatty acids Commensal microbiota Inhibition of NF-κB pathway
ATP = adenosine triphosphate; DC = dendritic cell; FR = folate receptor; FXR = farnesoid X receptor; GPR = G protein coupled receptor; IBD = inflammatory bowel
disease; IDO = indolamine 2,3-dioxygenase; IL = interleukin; NKT cell = natural killer T cell; TGR5 = transmembrane G coupled receptor 5; Th17 = IL-17 producing T
helper cells; TNF = tumour necrosis factor; Treg = regulatory T cells
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We have summarised the complex networks that regulate
the recognition of microbial metabolites by the host. In the
next section we discuss strategies targeting those for poten-
tial therapeutic interventions in the clinic.
Clinical perspectives of potential
interventions on interactions of
microbial-derived metabolites and the
host
At the moment, most treatments used for intestinal dis-
eases, such as IBD, modulate the immune response of the
host. Steroids, thiopurines, TNF antagonists and integrin
blockers act in this way [126]. In future, direct interven-
tions on host-microbe interactions may be an attractive op-
tion for the treatment of intestinal diseases. Currently, there
are several ways being discussed on how host-microbe in-
teractions can be influenced for therapeutic strategies, such
as the modification of the diet, the application of antibiot-
ics, the administration of probiotics and faecal microbiota
transplantation. In general, first clinical trials are being un-
dertaken to investigate these interventions in certain con-
ditions, such as IBD and irritable bowel syndrome (IBS).
However, information on detailed molecular mechanisms
is still in its infancy. In a crossover study with IBS patients,
a diet with low fermentable oligosaccharides, disacchar-
ides, monosaccharides, and polyols (FODMAPs) reduced
gastrointestinal symptoms as compared with a regular diet
[127]. FODMAPs define a group of short-chain carbohy-
drates, such as oligosaccharides (fructans and galactans),
disaccharides (lactose), monosaccharides (fructose, gluc-
ose in excess), and polyols (sorbitol, mannitol) that are in-
completely resorbed in the small intestine and then fermen-
ted in the colon [128]. A FODMAP diet is associated with
reduced numbers of Bifidobacteria in the intestinal micro-
biota. The absolute numbers of bacteria in individuals on
the FODMAP diet was reduced; the numbers of butyrate-
producing bacteria (Akkermansia muciniphila, Ruminococ-
cus gnavus) and the Clostridium cluster XIVa were de-
creased [129]. It is likely that bacterial-derived metabolites
in individuals with a FODMAP diet are reduced, which af-
fects immune responses, motility and nociception.
Antibiotics
Antibiotics can be used for the treatment of patients with
IBD [130], IBS [131], small intestinal bacterial overgrowth
[132] and pouchitis [133]. In a multicentre double blinded
study in patients with moderately active Crohn’s disease,
treatment with the nonabsorbable antibiotic rifaximin in-
duced remission in 62% of patients [130]. In the placebo-
treated group 43% of patients were in remission after the
12-week follow-up period [130]. Most patients with
Crohn’s disease need intestinal resection at some point dur-
ing the course of their disease. Treatment of patients with
metronidazole for 3 months after resection may prevent re-
currence of the disease [14].
When these patients receive active care with early endo-
scopy after 6 months, the therapy can be adapted to the
endoscopic findings with thiopurines or TNF antagonists.
The active care group in this study showed a better out-
come than patients not receiving early endoscopy [14].
In two double-blinded placebo-controlled trials in patients
with IBS without constipation, the patients received rifax-
imin at a dose of 550 mg three times daily for 2 weeks
and were followed up for a 10-week post-treatment period
[131]. Patients treated with rifaximin showed a significant
reduction of symptoms, especially bloating. This means
that a short period of treatment with rifaximin leads to
a sustained benefit in IBS patients without constipation.
However, the use of antibiotics in patients with chronic in-
testinal conditions needs to be considered carefully. In par-
ticular, the occurrence of antibiotic resistance needs to be
taken into account. In current clinical practice we do not
test changes in the composition of the microbiota in pa-
tients treated with antibiotics. In treatment-naïve paediat-
ric Crohn’s disease patients, the analysis of rectal biopsies
revealed an increased abundance of Enterobacteriaceae,
Pasteurellacaea, Veillonellaceae, and Fusobacteriaceae,
and decreased abundance in Erysipelotrichales, Bacter-
oidales, and Clostridiales [23]. The degree of dysbiosis
correlated with disease activity. Earlier use of antibiotics
amplified the dysbiosis associated with Crohn’s activity.
This means that the careful analysis of patients and defin-
ing of subgroups will be required in future to identify the
individuals who benefit from treatments with antibiotics
and to avoid treatments in patients who will not respond or
even relapse.
Probiotics
Preparations of live bacteria are effective for the treatment
of IBD. For example, E. coli Nissle 1917 can be used
for the induction and maintenance of remission in patients
with moderate ulcerative colitis with the same efficacy
as treatment with mesalazine [88]. VSL#3 probiotic mix-
ture contains eight different Lactobacillus strains (Lacto-
bacillus acidophilus, L. bulgaricus, L casei, L. plantarum,
Streptococcus thermophilus, Bifidobacterium breve, B. in-
fantis, and B. longum). Randomised controlled clinical tri-
als showed that VSL#3 could prevent recurrence of
pouchitis in chronic relapsing pouchitis [134]. The addition
of VSL#3 to mesalazine and steroids in newly diagnosed
ulcerative colitis patients may induce higher remissions
rates [135]. In general, probiotics are considered as safe
medications, but they also can harm. When germ-free im-
munocompromised animals are mono-colonised with E.
coli Nissle, the animals die within 10 days [136]. E. coli
Nissle is characterised by the expression of H1 flagella and
type 1 fimbriae that mediate adhesion to epithelial cells.
To survive in the gastrointestinal tract with its dense pop-
ulation of microbes, a probiotic needs to be extremely fit.
Perhaps the H1 flagella and type 1 fimbriae offer E. coli
Nissle an advantage in this particular microenvironment,
but may also explain the potential pathogenicity in selected
conditions [137]. Most strains do not colonise and are just
expelled. This means that probiotics needs to be given re-
peatedly and may explain disappointing results in clinical
trials.
Faecal microbiota transplantation
Faecal microbiota transplantation (FMT) is successful for
the treatment of recurrent Clostridium difficile infections
[138]. There have been case reports that FMT is also be-
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neficial for other gastrointestinal disorders associated with
dysbiosis, such as IBD. Two recent randomised controlled
studies have reported the efficacy of FMT for the treatment
of ulcerative colitis [139, 140]. In one study, remission was
observed in patients with mild to moderate active ulcerat-
ive colitis [139]. Seventy-five individuals received weekly
FMT from six donors or placebo (water) via retention en-
ema. Interim analysis showed a negative result. The addi-
tional analysis of 22 participants, who had already been en-
rolled into the study, after the interim analysis, gave a sig-
nificant positive outcome for the endpoint remission. These
22 participants had received the FMT from one donor.
This indicates that the faecal microbiota transplants vary
significantly between donors and influences the results of
the transplantation. In the study by Rossen et al. patients
with mild to moderate active ulcerative colitis were treated
with donor stool or autologous FMT (infusion of their own
stool) via a nasoduodenal tube [140]. There was no differ-
ence between the two groups [140]. The different route of
administration of the FMT (nasoduodenal tube vs enema)
and the fact that immunosuppression was allowed may ex-
plain the different outcome of the study by Moayyedi et
al., compared with the study by Rossen et al. [139, 140].
The quantity and quality of species reaching the colon may
be altered after administration of FMT via naso-duodenal
tube. Also, immunosuppression may facilitate the engraft-
ment of the transplanted microbiota. We still do not have
enough information on transplantation of the microbiota
and how their metabolites affect the host. In complex in-
testinal diseases, such as IBD, the effects of FMT seem to
be less beneficial than for C. difficile infections, because
the underlying immune mechanism in the genetically pre-
disposed host may affect the mcicrobiome. Whether the
transplant perpetuates in the recipient is not known. The
success of the transplantation depends on the composition
of the microbiota in the donor. However, a healthy donor
flora is not defined. This means that the criteria for select-
ing appropriate donors have not been established yet.
Conclusions
Advances in high-throughput sequencing technologies
have helped us to understand the complexity of the intest-
inal microbiome. We begin to appreciate that not only the
microorganisms by themselves but also the metabolites of
these organisms affect the functions of our own bodies.
Recent research has started to elucidate the receptors by
which the host recognises the metabolites produced by con-
stituents of the microbiome. However, the acquired know-
ledge on host-microbiome relationships is only starting to
be used in clinical practice for the treatment of intestinal
diseases, such as IBD. In future, the development of novel
ligands or antagonists of metabolite-recognition receptors
may offer interesting approaches for the treatment of intest-
inal diseases.
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Figures (large format)
Figure 1
Identification of disease-associated bacterial consortia in the gut. The bacteria coated with IgA in faecal material can be labelled with an
antibody directed against IgA. IgA-coated bacteria are then enriched by magnetic-activated cell sorting (MACS), purified by fluorescence-
activated cell sorting (FACS) and sequenced by 16S ribosomal RNA sequencing to identify the IgA coated genera.
Figure 2
Not only conserved structural motifs of microorganisms, but also bacteria-derived metabolites are recognised by the host immune system. A.
Pattern recognition receptors, such as Toll-like receptors, the scavenger receptors, the C type lectins, the RIG-I-like or the NOD-like receptors
recognise pathogen-associated molecular patterns, which are highly conserved structural motifs or molecules common to microbes and viruses.
B. Intestinal bacterial consortia metabolize food products and bile acids to short chain fatty acids (SCFA), secondary bile acids or vitamins. The
G protein coupled receptor (GPR) recognizes SCFA, the intracellular farnesoid X receptor (FXR) and the transmembrane G coupled receptor 5
(TGR5) sense secondary bile acids and retinoic acid is recognized by the retinoid X receptor to modulate host responses.
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Figure 3
Constituents of the gut microflora and immune system of the host metabolise the essential amino acid tryptophan. The essential amino
acid tryptophan is shuttled via the T-type amino acid transporter 1 (TAT1) across the intestinal barrier, metabolized by
indoleamine-2,3-dioxygenase (IDO) expressed in dendritic cells (DC) to kynurenine and kynurenic acid. Kynurenine supports the conversion of
T cells to regulatory T cells (Treg); kynurenic acid binds to the G-protein coupled receptor (GPR) 35 expressed by macrophages (Mac).
Tryptophan is also metabolized by constituents of the microflora to indole-3-aldehyde, which binds to the aryl hydrocarbon receptor (AhR)
facilitating IL-22 production by innate lymphoid cells (ILC)
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